90 results about "Proteoglycan" patented technology

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention relates to the technical field of functional nutritious food, in particular to multi-layer skin nutrition powder with a whole-spectrum skin growth and repair promoting effect and a preparation method and application thereof, the core of the multi-layer skin nutrition powder is composed of a collagen peptide system (60-62%), a proteoglycan system (20-22%) and the like, collagen peptide is compounded with three sources of cattle, fish and chicken, and the multi-layer skin nutrition powder has the advantages that the multi-layer skin nutrition powder is prepared; according to the present invention, with the combination of the following components, the skin structure and activity are jointly promoted by using the synergistic effect of the functional polypeptide compound (2.5-3.5%) and the plant active component (3.5-4.5%) rich in asiaticoside and procyanidine, and the nutrition enhancers (4-5%) such as L-ascorbic acid and amino acid chelated zinc and the food-grade auxiliary materials (8-10%) such as microcrystalline cellulose are integrated in the formula, such that the various systems achieve the synergistic effect so as to achieve the effect of nourishing the skin; through the synergistic compatibility of the three-source collagen peptide, the comprehensive supplement of various types of collagen in skin tissues is realized.

This invention belongs to the field of functional food processing technology, specifically relating to a method for improving the flavor of a chlorophyll-deficient Chlorella proteoglycan mutant. The method includes the following steps: S1, obtaining a Chlorella proteoglycan mutant strain; S2, centrifuging the Chlorella proteoglycan mutant strain and collecting the algal sludge, then pulverizing the collected algal sludge and dispersing it in water to obtain an algal powder suspension, then adding a compound enzyme to the algal powder suspension, and inactivating the enzyme after the reaction; S3, cooling the system to room temperature, adding glucose and stirring to dissolve, sterilizing, inoculating with a compound bacterial strain and fermenting, and sterilizing again after fermentation; S4, cooling the fermented system to room temperature, then adding β-cyclodextrin and stirring, and drying the system after stirring to obtain the algal protein product. This invention employs a synergistic process of compound enzymatic hydrolysis, compound bacterial fermentation, and β-cyclodextrin encapsulation to remove the off-flavor of the mutant algae from the source, significantly improving the flavor and enhancing the product's storage stability.

The present disclosure provides methods, compositions, and kits for the rapid release, labeling, and detection of O-glycans present on a glycoconjugate, such as a glycoprotein, glycopeptide, peptidoglycan, or proteoglycan of interest. The compositions and methods allow the released O-glycans to be subjected to high-throughput analysis.

The invention provides an application of OPO and a composition thereof in promoting intestinal development. The 1, 3-dioleoyl-2-palmitin disclosed by the invention can be used for up-regulating the transcriptional level of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2; therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

A treated human umbilical cord composition for use in the treatment of Perony's disease by in vivo injection in a subject in need thereof using an effective amount of the composition. The composition comprises a water-based human umbilical cord filtrate, wherein endogenous hyaluronic acid (HA) and / or hyaluronic acid, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycan (sGAG), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, metalloproteinase tissue inhibitor 1 (TIMP-1), and / or a pharmaceutically acceptable salt thereof in an amount effective to reduce the size of Pteroid disease plaques. The present invention relates to an aggregation glycan, or a combination thereof.

The application discloses a kind of preparation and application of microbial basic protein and adhesive proteoglycan hydrogel, belong to the field of biomaterials.Basic protein is extracted from microbial cells in the present application, using supramolecular assembly method, basic protein and acidic polysaccharide electrostatic assembly protein glycan gel material with strong tissue adhesion, the method is simple, widely available, and the cost is almost negligible.The tissue adhesive provided by the present application has immediate tissue adhesion performance, excellent biocompatibility and excellent antibacterial ability and hemostatic performance, which is beneficial to cope with different types of bleeding scene and irregular wound healing.Through cell compatibility and blood compatibility test, the results show that the material has excellent biocompatibility, and the basic protein has super strong bacteriostatic ability, avoids the invasion of foreign bacteria in the wound repair process, and has strong healing ability, greatly shortens the healing period of wound.

The invention discloses application of phentolamine in preparation of a medicine for treating intervertebral disc degeneration, and relates to the technical field of biomedicine.The phentolamine is applied to preparation of the medicine for treating intervertebral disc degeneration, inflammation inhibition, matrix expression promotion, matrix degradation inhibition and nucleus pulposus cell aging delaying are facilitated, and the effect of treating intervertebral disc degeneration is achieved. The height of the intervertebral disc can be increased, the integrity degree of a cell structure in the intervertebral disc can be improved, and the content of aggregation proteoglycan can be recovered.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

Provided is a method for analyzing proteoglycan, which enables simple analysis of proteoglycan in a sample.　Specifically, provided is a method for analyzing proteoglycan, comprising immersing or adding a sample containing proteoglycan into an aqueous solution containing a salt to obtain a liquid composition; and adding an alcohol to the liquid composition at a specific, relatively low concentration to obtain a purified precipitate, which is then subjected to proteoglycan analysis.

The present application relates to the technical field of intervertebral disc degeneration treatment and drug delivery, and discloses an injectable oxynate sodium functionalized hydrogel microsphere loaded with TGFbeta3 and application, by loading glycolysis inhibitor SO in the GelMA microsphere matrix and post-adsorbing TGFbeta3, on the one hand, SO is used to inhibit the excessive active glycolysis in the degenerative microenvironment, reduce lactic acid accumulation and relieve inflammation, on the other hand, TGFbeta3 is used to effectively promote the synthesis of collagen and proteoglycan, both of which synergistically act from the two aspects of metabolic regulation and matrix synthesis, and jointly promote the recovery of intervertebral disc homeostasis, therefore, the oxynate sodium functionalized microsphere loaded with TGFbeta3 constructed by the present application can realize the synergistic treatment of multiple targets and multiple pathways by synchronously delivering metabolic regulators and synthesis promoters, so as to more effectively delay or reverse the intervertebral disc degeneration process, and finally achieve the beneficial effect of the double repair effect of simultaneously regulating abnormal glycolysis metabolism of degenerative nucleus pulposus cells and promoting extracellular matrix synthesis.

The invention provides a preparation method and application of a dairy product for promoting development of an intestinal tract glycocalyx layer. Comprising a specific dose of casein phosphopeptides, and can up-regulate the transcriptional levels of a coding gene gpc1 of phospholipid globulin glycan, a coding gene has1 of hyaluronic acid synthetase 1, a coding gene has2 of hyaluronic acid synthetase 2, a coding gene has3 of hyaluronic acid synthetase 3, a coding gene ext1 of exosome glycosyltransferase 1 and a coding gene ext2 of exosome glycosyltransferase 2. Therefore, the development of a protein skeleton of the glycocalyx layer, the synthesis of hyaluronic acid and the synthesis of heparan sulfate are promoted, the development of the glycocalyx layer is further promoted, and the effects of improving the intestinal barrier, regulating the intestinal flora and improving the intestinal health are achieved.

This invention discloses a Chlorella heptapeptide TGPLGSR with multi-target lipid-lowering activity, its preparation method, and its applications. The amino acid sequence of this heptapeptide is Thr-Gly-Pro-Leu-Gly-Ser-Arg. The preparation method includes: performing ultraviolet and electroporation combined mutagenesis on wild-type Chlorella proteoglycans to obtain a high-protein-content mutant algal strain; obtaining algal protein through fermentation and synergistic extraction and purification with alcohols; directionally digesting the protein with alkaline protease, followed by enriching the active peptide components through ultrafiltration and gel chromatography; and finally, screening the heptapeptide using liquid chromatography-mass spectrometry (LC-MS), computer-aided prediction, and molecular docking techniques. This heptapeptide exhibits potent inhibitory activity against pancreatic lipase and can dose-dependently reduce the accumulation of triglycerides and cholesterol in 3T3-L1 cells. Its mechanism involves multiple target pathways, including inhibition of MMP-9, activation of AMPK phosphorylation, and downregulation of PNLIP, and it can be used to develop lipid-lowering functional foods or health products.

The present invention provides a novel method that can improve or maintain muscle quantity or muscle strength, and a novel method that can prevent obesity, or lower body fat percentage, or lower body fat quantity, or lower fat removal quantity. The proteoglycan used in the present invention is obtained by a method for producing the proteoglycan, comprising the steps of immersing a biological sample comprising the proteoglycan in an aqueous solution of a surfactant and collecting the solution after the immersion.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The present disclosure provides an agent capable of reducing endotoxin and used for reducing endotoxin in animal tissue-derived proteoglycan, and a method for producing proteoglycan and capable of reducing endotoxin. The agent of the present disclosure for reducing endotoxin in the animal tissue-derived proteoglycan comprises a nonionic surfactant.

The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.

The application relates to an anti-inflammatory and cartilage regeneration promoting material, a preparation method and application thereof, and belongs to the technical field of biomedical materials. The anti-inflammatory and cartilage regeneration promoting material comprises a PLGA (50:50) polymer material, and a huperzine A derivative dimer loaded on the PLGA (50:50) polymer material through 3D printing. The application also provides the use of the anti-inflammatory and cartilage regeneration promoting material in the preparation of anti-inflammatory, cartilage protection or cartilage regeneration promoting drugs. The PLGA / A10E scaffold has good biocompatibility, the PLGA / A10E scaffold degradation release liquid can effectively promote the differentiation of cartilage precursor cells into cartilage, and increase the formation of cartilage collagen matrix and cartilage proteoglycan. The in-vitro degradation liquid of the PLGA / A10E scaffold can promote the expression of SOX9 under non-inflammatory conditions; under LPS-mediated inflammatory conditions, the expression of MMP-13 can be inhibited, thereby promoting the synthesis of cartilage matrix and inhibiting the degradation of cartilage matrix.

When extracting PG from cartilage, other cartilage components such as collagen are extracted simultaneously and efficiently. [Solution] A method for producing a cartilage component mixture containing proteoglycans, comprising the steps of: immersing cartilage in an aqueous citric acid solution containing 0.01% by mass or more and less than 0.05% by mass at 30 to 80°C to obtain a cartilage component extract; and recovering cartilage components from the extract. .

The invention provides injectable hyaluronic acid hydrogel based on dynamic chemical bonds as well as a preparation method, application and a sol-gel conversion method of the injectable hyaluronic acid hydrogel, and belongs to the technical field of hydrogel. The preparation method comprises the following steps: oxidizing and modifying hyaluronic acid by adopting sodium periodate to obtain formylation modified hyaluronic acid, and carrying out Schiff base reaction on 3, 3 '-dithiodipropionyl hydrazine serving as a cross-linking agent and the formylation modified hyaluronic acid to prepare the injectable hyaluronic acid hydrogel. The HA-SS hydrogel provided by the invention not only has controllable gelation time, but also has excellent deformation resilience, elastic property and good biocompatibility, and can effectively simulate the structure and function of proteoglycan in a cartilage matrix. Due to the existence of the acylhydrazone bond and the disulfide bond, the injectable hyaluronic acid hydrogel based on the dynamic chemical bond has good rapid self-healing and pH / redox dual response performance.

The present invention relates to a fibrillar hydrogel comprising an aqueous solution and substantially aligned fibrils composed of collagen and at least one proteoglycan, having viscoelastic characteristics enabling its use in a wide range of industries, including but not limited to the food industry, biomaterial industry, pharmaceutic industry, and cosmetics, as well as for research purposes.

The present invention provides a simple, low-cost method for producing highly pure proteoglycan from a crushed cartilage tissue, a squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product. The crushed cartilage tissue, the squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product is immersed in or added to an aqueous solution containing salt, and alcohol is added to the resulting liquid composition in an amount to give a final concentration of 10 to 60% by volume to precipitate proteoglycans; alternatively, the crushed cartilage tissue, the squeezed product of the crushed cartilage tissue, or an extract of the crushed or squeezed product is immersed in or added to an aqueous solution containing salt and alcohol in an amount to give a final concentration of 10 to 60% by volume to precipitate proteoglycans.

The invention discloses preparation and application of a proteoglycan colloid material capable of rapidly stopping bleeding and promoting wound healing, and belongs to the field of biological materials. Basic amino acid rich in lysine or arginine is designed and expressed through molecular engineering, and then basic protein and hyaluronic acid with negative electricity are combined through a supramolecular assembly method to prepare a proteoglycan material with antibacterial ability. Then, recombinant mucoprotein rich in tyrosine is designed and expressed, and a DOPA adhesion group is formed through tyrosinase modification, so that the instant adhesion of the tissue adhesion material is enhanced. The amino acid of the basic protein remarkably enhances the interaction of various molecules of proteoglycan, meanwhile, the basic amino acid endows the tissue adhesive with excellent antibacterial ability, and the tissue adhesive provided by the invention has instant tissue adhesion performance, excellent biocompatibility and excellent antibacterial ability and hemostatic performance, and is suitable for being used in the field of medical instruments. The healing of different types of bleeding scenes and irregular wounds is facilitated.

The application discloses an IGF2BP2-m6A-VCAN-TLR2 signal axis in the preparation of a drug for treating intrahepatic cholangiocarcinoma lymphatic metastasis. In view of the problems of unknown intrahepatic cholangiocarcinoma lymphatic metastasis mechanism and lack of effective target, the application finds and verifies a new pathway that from insulin-like growth factor 2 mRNA binding protein 2, m6A modification regulates the expression of multi-functional proteoglycan, and then activates Toll-like receptor 2 signal, promotes macrophage secretion of vascular endothelial growth factor C and drives lymphatic metastasis. Based on this, the application provides an inhibitor targeting the signal axis, in particular, a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit cholangiocarcinoma cell migration, invasion and epithelial mesenchymal transition, reduce macrophage secretion of vascular endothelial growth factor C, and effectively inhibit tumor growth and lymphatic metastasis in a naked mouse popliteal lymph node metastasis model and a spontaneous cholangiocarcinoma model. The compound presents a synergistic effect in combination with gemcitabine and cisplatin.

The application discloses a composition for promoting joint health, a preparation method and application, and relates to the field of food.The composition comprises the following components in parts by weight: animal protein: 20-80; non-denatured type II collagen: 0.2-1; sodium hyaluronate: 0.5-2; proteoglycan: 0.5-2; sour cherry extract: 3-10; and calcium beta-hydroxy-beta-methylbutyrate: 5-20.The application takes non-denatured type II collagen as a main efficacy component, and additionally adds animal protein, sodium hyaluronate, proteoglycan, sour cherry extract and calcium beta-hydroxy-beta-methylbutyrate, synergistically acts through the multiple efficacy components, relieves joint discomfort through multiple pathways, maintains muscle health, and enables the product to have the optimal effect of repairing joint damage, improving joint and skeletal muscle health.

The application discloses a pharmaceutical composition for promoting angiogenesis and tissue regeneration and application thereof. The pharmaceutical composition comprises a cysteine-rich acidic secretory protein, a biglycan and a collagen XV alpha 1 chain. The application can promote angiogenesis and improve the tissue regeneration efficiency of bone, cartilage and skin defect areas through a biomaterial system loaded with the three types of proteins.

Radiopharmaceuticals and conjugates targeting GPC3, as well as their compositions and uses, are provided herein. In one embodiment, a conjugate comprising a peptide having avidity to GPC3 and a metal chelating agent configured to bind to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. The conjugate described herein may further comprise a radionuclide. In one embodiment, a radiopharmaceutical comprising a peptide and a metal chelating agent binding to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. Methods for treating cancer by administering the radiopharmaceuticals, conjugates, and compositions thereof are further provided herein.

The aim is to prevent and / or improve skin conditions that negatively affect skin appearance, such as wrinkles and sagging, by promoting the formation of cyclic collagen. [Solution] Screening was conducted on the expression of proteoglycan-related genes involved in proteoglycan formation, and it was found that rosehip extract or safflower extract increases the gene expression of persican and periostin, which are proteoglycan-related genes. Thus, rosehip extract or safflower extract was identified as a promoter of cyclic collagen formation.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.